Search

Displaying results 7991 - 8000 of 8515 in total
  1. Drug

    AVP-21D9

    go.drugbank.com/drugs/DB17798
    Investigational

    AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.[A259522]

  2. Drug

    Fluoroacetic acid F-18

    go.drugbank.com/drugs/DB15202
    Investigational

    Fluoroacetic acid F-18 is under investigation in clinical trial NCT01320787 (18-F-Fluoroacetate as PET Imaging Agent).

  3. Drug

    Forodesine

    go.drugbank.com/drugs/DB06185
    Investigational

    Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic

  4. Drug

    Etiprednol dicloacetate

    go.drugbank.com/drugs/DB05442
    Investigational

    Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease.

  5. Drug

    Altanserin

    go.drugbank.com/drugs/DB19972
    Investigational

    Altanserin has a monoisotopic molecular weight of 411.14 Da.

  6. Drug

    Vicasinabin

    go.drugbank.com/drugs/DB21587
    Investigational

    Vicasinabin has a monoisotopic molecular weight of 358.2 Da.

  7. Drug

    Ofirnoflast

    go.drugbank.com/drugs/DB21679
    Investigational

    Ofirnoflast has a monoisotopic molecular weight of 501.15 Da.

  8. Drug

    Eftilagimod alfa

    go.drugbank.com/drugs/DB16150
    Investigational

    Eftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).

  9. Drug

    TG-1042

    go.drugbank.com/drugs/DB18435
    Investigational

    TG-1042 (formerly known as ASN-002) is a recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene.

  10. Drug

    ARX517

    go.drugbank.com/drugs/DB23076
    Investigational

    ARX517 is under investigation in clinical trial NCT04662580 (ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer).